机译:影响CD19特异性CAR-T细胞治疗后的无进展生存的因素进行复发/难治性侵袭性B细胞非霍奇金淋巴瘤
Fred Hutchinson Canc Res Ctr Div Clin Res 1124 Columbia St Seattle WA 98104 USA;
Fred Hutchinson Canc Res Ctr Div Clin Res 1124 Columbia St Seattle WA 98104 USA;
Fred Hutchinson Canc Res Ctr Div Clin Res 1124 Columbia St Seattle WA 98104 USA;
Fred Hutchinson Canc Res Ctr 1124 Columbia St Seattle WA 98104 USA;
Fred Hutchinson Canc Res Ctr Dept Clin Biostat 1124 Columbia St Seattle WA 98104 USA;
Fred Hutchinson Canc Res Ctr Div Clin Res 1124 Columbia St Seattle WA 98104 USA;
Juno Therapeut Inc Seattle WA USA;
Fred Hutchinson Canc Res Ctr Div Clin Res 1124 Columbia St Seattle WA 98104 USA;
Fred Hutchinson Canc Res Ctr Div Clin Res 1124 Columbia St Seattle WA 98104 USA;
Univ Washington Dept Lab Med Seattle WA 98195 USA;
Univ Washington Dept Lab Med Seattle WA 98195 USA;
Fred Hutchinson Canc Res Ctr Div Clin Res 1124 Columbia St Seattle WA 98104 USA;
Fred Hutchinson Canc Res Ctr Div Clin Res 1124 Columbia St Seattle WA 98104 USA;
Fred Hutchinson Canc Res Ctr Div Clin Res 1124 Columbia St Seattle WA 98104 USA;
Fred Hutchinson Canc Res Ctr Div Clin Res 1124 Columbia St Seattle WA 98104 USA;
Fred Hutchinson Canc Res Ctr Div Clin Res 1124 Columbia St Seattle WA 98104 USA;
Univ Washington Fred Hutchinson Canc Res Ctr Seattle WA 98195 USA;
Fred Hutchinson Canc Res Ctr Div Clin Res 1124 Columbia St Seattle WA 98104 USA;
Fred Hutchinson Canc Res Ctr Div Clin Res 1124 Columbia St Seattle WA 98104 USA;
Fred Hutchinson Canc Res Ctr Div Clin Res 1124 Columbia St Seattle WA 98104 USA;
Fred Hutchinson Canc Res Ctr Div Clin Res 1124 Columbia St Seattle WA 98104 USA;
Fred Hutchinson Canc Res Ctr Div Clin Res 1124 Columbia St Seattle WA 98104 USA;
Fred Hutchinson Canc Res Ctr Div Clin Res 1124 Columbia St Seattle WA 98104 USA;
Fred Hutchinson Canc Res Ctr Div Clin Res 1124 Columbia St Seattle WA 98104 USA;
Fred Hutchinson Canc Res Ctr Div Clin Res 1124 Columbia St Seattle WA 98104 USA;
Fred Hutchinson Canc Res Ctr Div Clin Res 1124 Columbia St Seattle WA 98104 USA;
Fred Hutchinson Canc Res Ctr Div Clin Res 1124 Columbia St Seattle WA 98104 USA;
机译:影响CD19特异性CAR-T细胞治疗后的无进展生存的因素进行复发/难治性侵袭性B细胞非霍奇金淋巴瘤
机译:泼尼松,依托泊苷和环磷酰胺的节律疗法可降低复发或难治性非霍奇金淋巴瘤患者的血清VEGF和循环内皮细胞水平,并提高应答率和无进展生存率
机译:Axicabtagene ciloleucel(KTE-C19),一种抗CD19 CAR T疗法,用于治疗复发/难治性侵袭性B细胞非霍奇金淋巴瘤
机译:化疗后犬B细胞淋巴瘤的延长缓解和存活和低剂量率半体放射治疗
机译:免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性:RU051417I-R-ICE(利妥昔单抗-异环磷酰胺-卡铂-依托泊苷)与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤(DLBCL)。
机译:Axicabtagene ciloleucel(KTE-C19)一种抗CD19 CAR T疗法用于治疗复发/难治性侵袭性B细胞非霍奇金淋巴瘤
机译:I阶段I的19-28z Car-T细胞的试验高剂量治疗和自体移植(HDT-ASCT)进行复发和难治性(R / R)B细胞非霍奇金淋巴瘤(B-NHL)